<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00058188</url>
  </required_header>
  <id_info>
    <org_study_id>NU 02U1</org_study_id>
    <nct_id>NCT00058188</nct_id>
  </id_info>
  <brief_title>Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation</brief_title>
  <official_title>A Phase III Randomized Study of Zolendronate Bisphosphonate Therapy for the Prevention of Bone Loss in Men With Prostate Cancer Receiving Long-Term Androgen Deprivation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Zoledronate may prevent bone loss associated with long term androgen deprivation&#xD;
      therapy. It is not yet known whether zoledronate combined with calcium is more effective than&#xD;
      calcium alone in preventing bone loss.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of zoledronate combined with&#xD;
      calcium with that of calcium alone in preventing bone loss in patients with stage III or&#xD;
      stage IV prostate cancer who have received long-term androgen deprivation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare bone loss in patients receiving long-term androgen deprivation therapy for stage&#xD;
           III or IV prostate cancer when treated with supportive care with vs without zoledronate.&#xD;
&#xD;
        -  Compare the percentage change in lumbar spine and hip bone density in patients treated&#xD;
           with these regimens.&#xD;
&#xD;
        -  Compare markers of bone formation and resorption in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  Compare the incidence of skeletal events (pathologic and non-pathologic bone fractures,&#xD;
           spinal cord compression, surgery to bone, and radiotherapy to bone) in patients treated&#xD;
           with these regimens.&#xD;
&#xD;
        -  Compare the incidence of new or progressive bone metastatic disease in patients treated&#xD;
           with these regimens.&#xD;
&#xD;
        -  Compare the survival rate of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to race (black vs other). Patients are randomized&#xD;
      to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive zoledronate IV over 15 minutes on day 1 and oral calcium&#xD;
           gluconate and oral cholecalciferol daily. Courses repeat every 3 months for 12 months in&#xD;
           the absence of toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive oral calcium gluconate and oral cholecalciferol as in arm I.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 72 patients (36 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Closed by the research committee&#xD;
  </why_stopped>
  <start_date type="Actual">March 2003</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Density Change as Measured by Dual-energy X-ray Absorptiometry From Baseline to 13 Months</measure>
    <time_frame>Bone scan taken at baseline and month 13</time_frame>
    <description>To assess bone density change as measured by dual-energy x-ray absorptiometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Lumbar Spine and Hip Bone Density as Measured by Plain Film X-rays of Lumbar Spine and Pelvis From Baseline to 13 Months</measure>
    <time_frame>Lumbar spine and hip bone density taken at baseline and month 13.</time_frame>
    <description>To assess the percentage change in lumbar spine and hip bone density as measured by plain film x-rays of lumbar spine and pelvis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Bone Formation and Resorption</measure>
    <time_frame>Bone alkaline phosphatase taken at baseline, month 6 and month 13.</time_frame>
    <description>To assess markers of bone formation and resorption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Skeletal Events (Pathologic and Non-pathologic Bone Fractures, Spinal Cord Compression, Surgery to Bone, and Radiotherapy to Bone)</measure>
    <time_frame>PSA taken at baseline, month 3, month 6, month 9, month 12 and month 13. CT scan of abdomen and pelvis taken at baseline and month 13. Serum testosterone, estradiol, parathyroid taken at baseline, month 6 and month 13.</time_frame>
    <description>To assess the incidence of skeletal events (pathologic and non-pathologic bone fractures, spinal cord compression, surgery to bone, and radiotherapy to bone)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of New or Progressive Bone Metastatic Disease</measure>
    <time_frame>Serum osteocalcin and serum bone alkaline phosphatase taken at baseline, month 6 and month 13.</time_frame>
    <description>To assess the incidence of new or progressive bone metastatic disease</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive zoledronate IV over 15 minutes on day 1 and oral calcium gluconate and oral cholecalciferol daily. Courses repeat every 3 months for 12 months in the absence of toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive oral calcium gluconate and oral cholecalciferol as in arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cholecalciferol</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcium gluconate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed prostate cancer&#xD;
&#xD;
               -  Stage III or IV disease&#xD;
&#xD;
          -  Received at least 3 months of prior androgen deprivation therapy (no maximum&#xD;
             amount/time) by either surgical or medical castration&#xD;
&#xD;
               -  Medical castration may be by intermittent or continuous androgen suppression via&#xD;
                  single- or combined-drug androgen blockade&#xD;
&#xD;
          -  Continued concurrent androgen deprivation therapy required throughout study&#xD;
             participation&#xD;
&#xD;
          -  No bone metastases by baseline bone scan&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 1 year&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT less than 3 times ULN&#xD;
&#xD;
          -  No chronic liver disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No Paget's disease&#xD;
&#xD;
          -  No Cushing's disease&#xD;
&#xD;
          -  No hyperthyroidism&#xD;
&#xD;
          -  No hyperprolactinemia&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Prior chemotherapy for prostate cancer allowed&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 12 months since prior suppressive doses of thyroxine or calcitonin&#xD;
&#xD;
          -  More than 6 months since prior corticosteroids&#xD;
&#xD;
          -  Concurrent corticosteroids allowed (after enrollment on study)&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Prior radiotherapy for prostate cancer allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 12 months since prior bisphosphonate therapy (oral or IV)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles L. Bennett, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Lakeside Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John H. Stroger Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 7, 2003</study_first_submitted>
  <study_first_submitted_qc>April 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2003</study_first_posted>
  <results_first_submitted>October 23, 2020</results_first_submitted>
  <results_first_submitted_qc>October 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 19, 2020</results_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Zoledronic Acid</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>PIs departure from the institution was sudden and due unforeseen serious circumstances. Due to this, no data was collected for this study nor can be reported on.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment With Zoledronate, Calcium and Cholecalciferol</title>
          <description>Patients receive zoledronate IV over 15 minutes on day 1 and oral calcium gluconate and oral cholecalciferol daily. Courses repeat every 3 months for 12 months in the absence of toxicity.&#xD;
cholecalciferol: Given orally&#xD;
calcium gluconate: Given orally&#xD;
zoledronic acid: Given IV</description>
        </group>
        <group group_id="P2">
          <title>Treatment With Calcium and Cholecalciferol</title>
          <description>Patients receive oral calcium gluconate and oral cholecalciferol as in arm I.&#xD;
cholecalciferol: Given orally&#xD;
calcium gluconate: Given orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Due to the unique situation of the PI, no data was collected for this study nor can be reported on.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment With Zoledronate, Calcium and Cholecalciferol</title>
          <description>Patients receive zoledronate IV over 15 minutes on day 1 and oral calcium gluconate and oral cholecalciferol daily. Courses repeat every 3 months for 12 months in the absence of toxicity.&#xD;
cholecalciferol: Given orally&#xD;
calcium gluconate: Given orally&#xD;
zoledronic acid: Given IV</description>
        </group>
        <group group_id="B2">
          <title>Treatment With Calcium and Cholecalciferol</title>
          <description>Patients receive oral calcium gluconate and oral cholecalciferol as in arm I.&#xD;
cholecalciferol: Given orally&#xD;
calcium gluconate: Given orally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone Density Change as Measured by Dual-energy X-ray Absorptiometry From Baseline to 13 Months</title>
        <description>To assess bone density change as measured by dual-energy x-ray absorptiometry</description>
        <time_frame>Bone scan taken at baseline and month 13</time_frame>
        <population>Due to the unique situation of the PI, no data was collected for this study nor can be reported on.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Zoledronate, Calcium and Cholecalciferol</title>
            <description>Patients receive zoledronate IV over 15 minutes on day 1 and oral calcium gluconate and oral cholecalciferol daily. Courses repeat every 3 months for 12 months in the absence of toxicity.&#xD;
cholecalciferol: Given orally&#xD;
calcium gluconate: Given orally&#xD;
zoledronic acid: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Treatment With Calcium and Cholecalciferol</title>
            <description>Patients receive oral calcium gluconate and oral cholecalciferol as in arm I.&#xD;
cholecalciferol: Given orally&#xD;
calcium gluconate: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Density Change as Measured by Dual-energy X-ray Absorptiometry From Baseline to 13 Months</title>
          <description>To assess bone density change as measured by dual-energy x-ray absorptiometry</description>
          <population>Due to the unique situation of the PI, no data was collected for this study nor can be reported on.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Lumbar Spine and Hip Bone Density as Measured by Plain Film X-rays of Lumbar Spine and Pelvis From Baseline to 13 Months</title>
        <description>To assess the percentage change in lumbar spine and hip bone density as measured by plain film x-rays of lumbar spine and pelvis</description>
        <time_frame>Lumbar spine and hip bone density taken at baseline and month 13.</time_frame>
        <population>Due to the unique situation of the PI, no data was collected for this study nor can be reported on.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Zoledronate, Calcium and Cholecalciferol</title>
            <description>Patients receive zoledronate IV over 15 minutes on day 1 and oral calcium gluconate and oral cholecalciferol daily. Courses repeat every 3 months for 12 months in the absence of toxicity.&#xD;
cholecalciferol: Given orally&#xD;
calcium gluconate: Given orally&#xD;
zoledronic acid: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Treatment With Calcium and Cholecalciferol</title>
            <description>Patients receive oral calcium gluconate and oral cholecalciferol as in arm I.&#xD;
cholecalciferol: Given orally&#xD;
calcium gluconate: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Lumbar Spine and Hip Bone Density as Measured by Plain Film X-rays of Lumbar Spine and Pelvis From Baseline to 13 Months</title>
          <description>To assess the percentage change in lumbar spine and hip bone density as measured by plain film x-rays of lumbar spine and pelvis</description>
          <population>Due to the unique situation of the PI, no data was collected for this study nor can be reported on.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Bone Formation and Resorption</title>
        <description>To assess markers of bone formation and resorption.</description>
        <time_frame>Bone alkaline phosphatase taken at baseline, month 6 and month 13.</time_frame>
        <population>Due to the unique situation of the PI, no data was collected for this study nor can be reported on.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Zoledronate, Calcium and Cholecalciferol</title>
            <description>Patients receive zoledronate IV over 15 minutes on day 1 and oral calcium gluconate and oral cholecalciferol daily. Courses repeat every 3 months for 12 months in the absence of toxicity.&#xD;
cholecalciferol: Given orally&#xD;
calcium gluconate: Given orally&#xD;
zoledronic acid: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Treatment With Calcium and Cholecalciferol</title>
            <description>Patients receive oral calcium gluconate and oral cholecalciferol as in arm I.&#xD;
cholecalciferol: Given orally&#xD;
calcium gluconate: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Markers of Bone Formation and Resorption</title>
          <description>To assess markers of bone formation and resorption.</description>
          <population>Due to the unique situation of the PI, no data was collected for this study nor can be reported on.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Skeletal Events (Pathologic and Non-pathologic Bone Fractures, Spinal Cord Compression, Surgery to Bone, and Radiotherapy to Bone)</title>
        <description>To assess the incidence of skeletal events (pathologic and non-pathologic bone fractures, spinal cord compression, surgery to bone, and radiotherapy to bone)</description>
        <time_frame>PSA taken at baseline, month 3, month 6, month 9, month 12 and month 13. CT scan of abdomen and pelvis taken at baseline and month 13. Serum testosterone, estradiol, parathyroid taken at baseline, month 6 and month 13.</time_frame>
        <population>Due to the unique situation of the PI, no data was collected for this study nor can be reported on.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Zoledronate, Calcium and Cholecalciferol</title>
            <description>Patients receive zoledronate IV over 15 minutes on day 1 and oral calcium gluconate and oral cholecalciferol daily. Courses repeat every 3 months for 12 months in the absence of toxicity.&#xD;
cholecalciferol: Given orally&#xD;
calcium gluconate: Given orally&#xD;
zoledronic acid: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Treatment With Calcium and Cholecalciferol</title>
            <description>Patients receive oral calcium gluconate and oral cholecalciferol as in arm I.&#xD;
cholecalciferol: Given orally&#xD;
calcium gluconate: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Skeletal Events (Pathologic and Non-pathologic Bone Fractures, Spinal Cord Compression, Surgery to Bone, and Radiotherapy to Bone)</title>
          <description>To assess the incidence of skeletal events (pathologic and non-pathologic bone fractures, spinal cord compression, surgery to bone, and radiotherapy to bone)</description>
          <population>Due to the unique situation of the PI, no data was collected for this study nor can be reported on.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of New or Progressive Bone Metastatic Disease</title>
        <description>To assess the incidence of new or progressive bone metastatic disease</description>
        <time_frame>Serum osteocalcin and serum bone alkaline phosphatase taken at baseline, month 6 and month 13.</time_frame>
        <population>Due to the unique situation of the PI, no data was collected for this study nor can be reported on.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Zoledronate, Calcium and Cholecalciferol</title>
            <description>Patients receive zoledronate IV over 15 minutes on day 1 and oral calcium gluconate and oral cholecalciferol daily. Courses repeat every 3 months for 12 months in the absence of toxicity.&#xD;
cholecalciferol: Given orally&#xD;
calcium gluconate: Given orally&#xD;
zoledronic acid: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Treatment With Calcium and Cholecalciferol</title>
            <description>Patients receive oral calcium gluconate and oral cholecalciferol as in arm I.&#xD;
cholecalciferol: Given orally&#xD;
calcium gluconate: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of New or Progressive Bone Metastatic Disease</title>
          <description>To assess the incidence of new or progressive bone metastatic disease</description>
          <population>Due to the unique situation of the PI, no data was collected for this study nor can be reported on.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events timeframe is not known. There is no data for this study.</time_frame>
      <desc>Due to the unique situation of the PI, no data was collected for this study nor can be reported on.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment With Zoledronate, Calcium and Cholecalciferol</title>
          <description>Patients receive zoledronate IV over 15 minutes on day 1 and oral calcium gluconate and oral cholecalciferol daily. Courses repeat every 3 months for 12 months in the absence of toxicity.&#xD;
cholecalciferol: Given orally&#xD;
calcium gluconate: Given orally&#xD;
zoledronic acid: Given IV</description>
        </group>
        <group group_id="E2">
          <title>Treatment With Calcium and Cholecalciferol</title>
          <description>Patients receive oral calcium gluconate and oral cholecalciferol as in arm I.&#xD;
cholecalciferol: Given orally&#xD;
calcium gluconate: Given orally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials Office</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-1301</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

